Azerbaijan has introduced one of the most comprehensive bans on vaping products, prohibiting the import, production, sale, and use of electronic cigarettes nationwide. The new legislation, which came into force on 1 April 2026, classifies nicotine-containing e-cigarettes as tobacco products and removes them entirely from the legal market. The restrictions extend to all components, including devices, cartridges and e-liquids, with authorities also introducing fines and product confiscation for violations. At the same time, heated tobacco products are explicitly excluded from the ban and will continue to be regulated separately. The move reflects a strict public health approach aimed at reducing nicotine use, but it also raises questions about enforcement, potential illicit markets, and the broader role of alternative products within tobacco control strategies.

Growing controversy is emerging around studies linking vaping to cancer, following the retraction of a high-profile review and mounting criticism of similar research. One widely cited paper was withdrawn after experts identified serious methodological flaws, including inconsistent data, deviations from the original protocol, and unsupported conclusions. Critics argue that some studies in this field rely on weak or mixed evidence—such as combining animal data, biomarkers, and populations that also smoke—making it difficult to draw clear causal links to cancer. The issue has gained further attention amid broader media coverage of new research suggesting potential cancer risks from vaping, intensifying debate over how such findings should be interpreted. Experts warn that flawed or overstated conclusions can shape public perception and policy before corrections are made, highlighting concerns about the speed at which misinformation can spread compared to scientific revisions. The discussion reflects wider tensions in evaluating emerging evidence on vaping, particularly in the absence of long-term data and the need to balance precaution with scientific rigour.

Growing scrutiny is being directed at the role of philanthropic funding in shaping EU tobacco and nicotine policy. The analysis explores how networks linked to Bloomberg Philanthropies have supported advocacy groups and NGOs active in European policy processes. Questions are being raised about the scale of financial influence and whether it may contribute to a more uniform policy agenda, particularly in areas such as taxation and regulation of nicotine products. The discussion highlights concerns around transparency, accountability, and the extent to which externally funded actors shape public health strategies within EU institutions.

Growing criticism is being directed at the European Commission’s handling of scientific evidence in shaping tobacco and nicotine policy. The discussion centres on claims that key findings—particularly those supporting harm reduction approaches—have been selectively downplayed or omitted in official evaluations. Critics argue that this selective use of data risks distorting the policy debate and undermining evidence-based decision-making. The issue is particularly significant as the EU prepares to revise its tobacco control framework, where interpretations of scientific evidence are likely to play a decisive role. At the heart of the debate lies a broader concern about transparency, credibility, and whether policymaking processes fully reflect the available body of research.

Growing evidence is reshaping the debate on the public health impact of vaping as it increasingly overtakes smoking among certain populations. Recent research highlights that the majority of e-cigarette users are current or former smokers, suggesting that use is largely concentrated among those already exposed to tobacco. Biomarker studies indicate that individuals who switch completely from smoking to e-cigarettes can experience substantial reductions—often exceeding 90%—in exposure to key toxicants linked to tobacco-related disease. At the same time, the findings emphasise that patterns such as dual use remain common and represent a more complex risk profile, with partial reductions in harm rather than complete elimination. The research underscores a broader shift towards viewing nicotine use along a continuum of risk, raising important questions about how harm reduction, cessation, and population-level outcomes should be balanced in public health policy.